Medoverine (Mebeverine Hydrochloride)

Mebeverine acts as a direct relaxant of gastrointestinal smooth muscle. It blocks calcium channels and reduces calcium influx into muscle cells, which diminishes abnormal contractions while preserving normal peristalsis, thereby alleviating spasm‑related pain.

The dosage of Medoverine is determined by the prescribing clinician based on the patient’s condition, severity of symptoms and individual response. The prescriber will select the appropriate strength and frequency according to local guidelines and product labeling.

Safety data for mebeverine in pregnancy and lactation are limited. The drug is not classified in a specific pregnancy category, so clinicians should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women.

To request Medoverine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mebeverine differs from anticholinergic agents such as hyoscine or dicyclomine because it does not have significant anticholinergic activity, resulting in fewer dry‑mouth and blurred‑vision side effects. Its calcium‑channel‑blocking action provides targeted smooth‑muscle relaxation, which many clinicians consider advantageous for IBS management.

Medoverine should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability and potency throughout its shelf life.

Medoverine is taken orally. The tablets (or other oral form) are swallowed whole with a glass of water, preferably with or without food as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional.

Serious adverse reactions, although rare, include severe allergic responses such as rash, angioedema, Stevens‑Johnson syndrome, and anaphylaxis. Cardiovascular events like arrhythmias have been reported in susceptible individuals. Prompt medical attention is required if any of these symptoms occur.

Medoverine is contraindicated in patients with known hypersensitivity to mebeverine or any of its excipients. Caution is advised for individuals with severe hepatic or renal impairment, and it should be avoided in patients taking other potent antispasmodics or medications that significantly prolong the QT interval.